| Literature DB >> 32256363 |
Feiyu Chen1, Zhangfeng Zhong1, Hor Yue Tan1, Wei Guo1, Cheng Zhang1, Chi-Wing Tan1, Sha Li1, Ning Wang1, Yibin Feng1.
Abstract
The potential values of Chinese herbal formulas in treating various diseases are well known. In addition to more than 2,000 years of history, herbal medicine is appreciated for its remarkable efficacy in a lot of cases, which warrants a role in public health care worldwide, especially in East Asian countries. Liver cancer is the second most fatal cancer across the world. Recent studies have extensively investigated the chemical profiles and pharmacological effects of Chinese herbal medicine formulas on liver cancer. Either through observational follow-up or experimental studies, multiple herbal formulas have benefits implicated in the management of liver cancer. However, complex composition of each formula imposes restrictions on promoting clinical practice and global recognition. Therefore, understanding the mode of action of Chinese herbal medicine formulas in depth may offer sufficient evidence for their clinical use. This review highlighted the chemical characteristics and molecular mechanisms of actions of prominent Chinese herbal medicine formulas and summarized the correlated findings on the potential use in liver cancer treatment. At last, the present progresses of Chinese herbal medicine formulas in the perspective of clinical trials are discussed.Entities:
Keywords: Chinese herbal medicine formula; alternative therapy; cancer; hepatocellular carcinoma; liver cancer
Year: 2020 PMID: 32256363 PMCID: PMC7093640 DOI: 10.3389/fphar.2020.00293
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1The roles of Chinese herbal medicine formulas in liver cancer treatment.
Figure 2The flowchart of the literatures search strategy, inclusion and exclusion criteria.
Chinese herbal medicine formulas for liver cancer treatment.
| Name of formula | Composition | Dosage or interval | Key findings | Mechanism of action | Reference |
|---|---|---|---|---|---|
| Compound | 60, 120, or 240 mg/kg per day for 12–16 weeks | Repressed proliferation of hepatic stellate cells and HepG2 cells, inhibited tumor growth in HCC rats | MAPK (mitogen-activated protein kinases)–regulated TGF (transforming growth factor)-β/Smad signaling pathway | ( | |
| Ciji Hua'ai Baosheng granule | 5.85, 2.93, or 1.46 g/mL per day for 10 days | Prolonged survival time of H22 mice model | Increasing serum IL-2 (interleukin 2), IFN-γ (Interferon-γ) and TNF-α, but decreased IL-6 levels in serum and tumor tissue | ( | |
| Dachaihu decoction | 50 mL/time twice a day (BID), for 5 days | Attenuated adverse reactions (fever, abdominal pain, , nausea and vomiting, insomnia) in HCC patients | NA | ( | |
| Dahuang Zhechong formula | In types of pill and capsule for 12 weeks to 12 months | Reduced fibrosis markers in liver fibrosis patients with Hepatitis B virus, potential benefits for liver cancer patients | NA | ( | |
| Danzhi Xiaoyao San | 250 mL/time BID, for 15 days | Tumor inhibition and reduced incidence of adverse reactions in HCC patients | NA | ( | |
| Fuzheng Jiedu Tongluo Fang | 2.65 mg/mL | Inhibited invasion of HepG2 cells. | MMP-2 (matrix metalloproteinase 2) and MMP-9 downregulation | ( | |
| Fuzheng Kang'ai Formula | 13.6 µmol/L | Blocked invasion and migration capacities in HepG2 cells | Reversing epithelial-to-mesenchymal transition | ( | |
| Fuzheng Yiliu decoction | 400 mg/mL | Inhibited tumor progression, invasion, and migration ability in MHC97-H cells | NA | ( | |
| Gansui Banxia Tang | 7.2–14.4 g/kg per day | Inhibited tumor growth in xenografted nude mice | Targeting Hsp90a (heat shock protein 90a), ATP1A1 (ATPase Na+/K+ transporting subunit α1) and STAT3 (Signal transducer and activator of transcription 3) proteins | ( | |
| NA | Alleviated the pain of patients and side effects, inhibited the proliferation of tumor cells in patients | NA | ( | ||
| Huanglian Jiedu decoction | 25, 50, and 100 mg/kg, BID, for 3 weeks | Attenuated cell progression in HepG2, MHCC97L cells; suppressed xenografted growth of nude mice | Targeting eukaryotic elongation factor 2 | ( | |
| JDF granule | 8 g/time BID | Prolonged survival of patients with unresectable HCC | NA | ( | |
| Jiedu Xiaozheng Yin | 200 mg/mL | Inhibited cell growth of HepG2 cells | Cell arrest at G0/G1 phase via regulated expressions of cyclin D and cyclin E | ( | |
| Ka-mi-kae-kyuk-tang | 3 times/week for 36 days | Anti–liver metastasis and invasiveness in C57BL/6 mice model | NA | ( | |
| KCT-01 | 5,000 mg/kg per day | Cell proliferation reduced in HepG2 and HepG2.2.15 cells; anti-HBV in C57BL/6 mice | Reduction in TNF-α, IL-6, and MCP (methyl-accepting chemotaxis proteins) mRNA synthesis | ( | |
| Liujunzi Decoction | BID for 9 days | Better scores in life quality and liver function (alanine aminotransferase, aspartate aminotransferase) in HCC patients | NA | ( | |
| Pien Tze Huang | 234 mg/kg per day | Anti–liver metastasis | Inhibition of epithelial-to-mesenchymal transition; regulation of Hif-1 (hypoxia-inducible factor 1) pathway | ( | |
| PHY906 | 800 mg BID | Median overall survival was 9.2 months in advanced HCC patients | Synergistically acting with chemotherapy | ( | |
| QHF (Q, Qingrejiedu; | 20, 40, 80, 160, and 320 µg/mL | Inhibited migration and invasion in HepG2 cells | Inhibitory action in migration and invasion activities | ( | |
| Qingyihuaji formula | NA | Anti–liver metastasis in nude mice | Reversing epithelial-to-mesenchymal transition | ( | |
| San-Huang-Xie Xin-Tang | 3.66 mg/mL | Cell proliferation decreased in HepG2 cells | p53 signaling and DNA damage | ( | |
| Shen-Ling-Bai-Zhu Powder | 0.075, 0.15, or 0.3 g/mL per day | Inhibited tumor growth and accelerated apoptosis in H22 mice model | Descending levels of tumor growth promoters signaling and apoptotic suppressor proteins | ( | |
| Shuangbai powder | BID for 7 days | Enhanced analgesic effect, reduced side effects, and improved patients' quality of life | NA | ( | |
| Shuihonghuazi formula | 757 mg/kg per day | Enhanced the organism immunity of cancer rats | Mediation of phosphatidylethanolamine | ( | |
| Sijunzi decoction | 300 mL/day, for 2 years | Reduced tumor recurrence and increased survival rate in HCC patients | Regulation of T lymphocytes and natural killer cells | ( | |
| Simo decoction | 300 mL/day | Recovery of gastrointestinal function and reduced complications in HCC patients | NA | ( | |
| Songyou Yin | 4 g/kg per day | Tumor suppression and metastasis inhibition in C57BL/6 mice | Enhancing immunity (CD4, CD8), reduced serum TGF-β1 and CD4 + CD25 + Foxp3 + Treg (regulatory T cells) proportion in PBMC (peripheral blood mononuclear cell), spleen lymphocytes, and TIL (tumor-infiltrating lymphocytes) | ( | |
| Weichang'an | 0.5 mL/day | Cytotoxicity in HCT-116 cells; reduced metastasis in nude mice | Decreasing expressions of β-catenin and MMP-7 | ( | |
| Xiaotongsan | Every day for 4 weeks | Relieved the pain of patients, decreased dosage of morphine | NA | ( | |
| Yanggan Huayu KangaiSan | 12 g/time, thrice a day | Inhibited anchorage-independent growth and induced caspase-mediated anoikis in Bel-7402 cells | Reducing glutamate aminotransferase, aspartate aminotransferase, serum total bilirubin, serum α-fetoprotein | ( | |
| Yanggan Jiedu Sangjie formula | 400 mg/mL | Inhibited anchorage-independent growth and induced caspase-mediated anoikis in Bel-7402 cells | ROS (reactive oxygen species) generation and PTK2 (PTK2 protein tyrosine kinase 2) downregulation | ( | |
| Yi Guan Jian | 400 mg/mL | Cell proliferation decreased in Bel-7402 cells | Anoikis induction and phosphorylation of p38 MAPK | ( | |
| Zuo Jin Wan | 19, 38, 76, 152, and 304 μg/mL | Inhibitory effects in SMMC-7721, BEL-7402, BEL-7404, HepG2 cells | Induction of mitochondria-dependent apoptosis | ( | |
| ZYD | 500, 1,000 μg/mL | Attenuated migratory and adhesion abilities in SMMC-7721 | Anti–hepatitis B virus, deregulations of Snail, MMP-2 and MMP-9 | ( |